Cargando…
Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study
BACKGROUND: The heritability of opioid use disorder has been widely investigated; however, the influence of specific genes on methadone treatment outcomes is not well understood. The association between response to methadone treatment and genes that are involved in substance use behaviors and reward...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672523/ https://www.ncbi.nlm.nih.gov/pubmed/26437921 http://dx.doi.org/10.1186/s13722-015-0040-7 |
_version_ | 1782404585304883200 |
---|---|
author | Bawor, Monica Dennis, Brittany B. Tan, Charlie Pare, Guillaume Varenbut, Michael Daiter, Jeff Plater, Carolyn Worster, Andrew Marsh, David C. Steiner, Meir Anglin, Rebecca Desai, Dipika Thabane, Lehana Samaan, Zainab |
author_facet | Bawor, Monica Dennis, Brittany B. Tan, Charlie Pare, Guillaume Varenbut, Michael Daiter, Jeff Plater, Carolyn Worster, Andrew Marsh, David C. Steiner, Meir Anglin, Rebecca Desai, Dipika Thabane, Lehana Samaan, Zainab |
author_sort | Bawor, Monica |
collection | PubMed |
description | BACKGROUND: The heritability of opioid use disorder has been widely investigated; however, the influence of specific genes on methadone treatment outcomes is not well understood. The association between response to methadone treatment and genes that are involved in substance use behaviors and reward mechanisms is poorly understood, despite evidence suggesting their contribution to opioid use disorder. The aim of this study was to investigate the effect of brain-derived neurotrophic factor (BDNF) and dopamine receptor D2 (DRD2) polymorphisms on continued opioid use among patients on methadone treatment for opioid use disorder. METHODS: BDNF 196G>A (rs6265) and DRD2-241A>G (rs1799978) genetic variants were examined in patients with opioid use disorder who were recruited from methadone treatment clinics across Southern Ontario, Canada. We collected demographic information, substance use history, blood for genetic analysis, and urine to measure opioid use. We used regression analysis to examine the association between continued opioid use and genetic variants, adjusting for age, sex, ethnicity, methadone dose, duration in treatment, and number of urine screens. RESULTS: Among 240 patients treated with methadone for opioid use disorder, 36.3 percent (n = 87) and 11.3 percent (n = 27) had at least one risk allele for rs6265 and rs1799978, respectively. These genetic variants were not significantly associated with continued opioid use while on methadone maintenance treatment [rs6265: odds ratio (OR) = 1.37, 95 % confidence interval (CI) = 0.792, 2.371, p = 0.264; rs1799978: OR 1.27, 95 % CI 0.511, 3.182, p = 0.603]. CONCLUSIONS: Despite an association of BDNFrs6265 and DRD2rs1799978 with addictive behaviors, these variants were not associated with continued illicit opioid use in patients treated with methadone. Problematic use of opioids throughout treatment with methadone may be attributed to nongenetic factors or a polygenic effect requiring further exploration. Additional research should focus on investigating these findings in larger samples and different populations. |
format | Online Article Text |
id | pubmed-4672523 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46725232015-12-09 Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study Bawor, Monica Dennis, Brittany B. Tan, Charlie Pare, Guillaume Varenbut, Michael Daiter, Jeff Plater, Carolyn Worster, Andrew Marsh, David C. Steiner, Meir Anglin, Rebecca Desai, Dipika Thabane, Lehana Samaan, Zainab Addict Sci Clin Pract Research BACKGROUND: The heritability of opioid use disorder has been widely investigated; however, the influence of specific genes on methadone treatment outcomes is not well understood. The association between response to methadone treatment and genes that are involved in substance use behaviors and reward mechanisms is poorly understood, despite evidence suggesting their contribution to opioid use disorder. The aim of this study was to investigate the effect of brain-derived neurotrophic factor (BDNF) and dopamine receptor D2 (DRD2) polymorphisms on continued opioid use among patients on methadone treatment for opioid use disorder. METHODS: BDNF 196G>A (rs6265) and DRD2-241A>G (rs1799978) genetic variants were examined in patients with opioid use disorder who were recruited from methadone treatment clinics across Southern Ontario, Canada. We collected demographic information, substance use history, blood for genetic analysis, and urine to measure opioid use. We used regression analysis to examine the association between continued opioid use and genetic variants, adjusting for age, sex, ethnicity, methadone dose, duration in treatment, and number of urine screens. RESULTS: Among 240 patients treated with methadone for opioid use disorder, 36.3 percent (n = 87) and 11.3 percent (n = 27) had at least one risk allele for rs6265 and rs1799978, respectively. These genetic variants were not significantly associated with continued opioid use while on methadone maintenance treatment [rs6265: odds ratio (OR) = 1.37, 95 % confidence interval (CI) = 0.792, 2.371, p = 0.264; rs1799978: OR 1.27, 95 % CI 0.511, 3.182, p = 0.603]. CONCLUSIONS: Despite an association of BDNFrs6265 and DRD2rs1799978 with addictive behaviors, these variants were not associated with continued illicit opioid use in patients treated with methadone. Problematic use of opioids throughout treatment with methadone may be attributed to nongenetic factors or a polygenic effect requiring further exploration. Additional research should focus on investigating these findings in larger samples and different populations. BioMed Central 2015-10-06 2015 /pmc/articles/PMC4672523/ /pubmed/26437921 http://dx.doi.org/10.1186/s13722-015-0040-7 Text en © Bawor et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Bawor, Monica Dennis, Brittany B. Tan, Charlie Pare, Guillaume Varenbut, Michael Daiter, Jeff Plater, Carolyn Worster, Andrew Marsh, David C. Steiner, Meir Anglin, Rebecca Desai, Dipika Thabane, Lehana Samaan, Zainab Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study |
title | Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study |
title_full | Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study |
title_fullStr | Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study |
title_full_unstemmed | Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study |
title_short | Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study |
title_sort | contribution of bdnf and drd2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672523/ https://www.ncbi.nlm.nih.gov/pubmed/26437921 http://dx.doi.org/10.1186/s13722-015-0040-7 |
work_keys_str_mv | AT bawormonica contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy AT dennisbrittanyb contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy AT tancharlie contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy AT pareguillaume contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy AT varenbutmichael contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy AT daiterjeff contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy AT platercarolyn contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy AT worsterandrew contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy AT marshdavidc contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy AT steinermeir contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy AT anglinrebecca contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy AT desaidipika contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy AT thabanelehana contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy AT samaanzainab contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy |